WallStreetZenWallStreetZen

NASDAQ: RPRX
Royalty Pharma PLC Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Royalty Pharma earnings were $765.0M for the trailing 12 months ending Sep 30, 2025, with -31.5% growth year over year. The latest RPRX earnings report on Sep 30, 2025 announced Q3 2025 earnings of $288.2M, up 855.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RPRX reported annual earnings of $859.0M, with -24.3% growth. The next RPRX earnings date is Feb 10, 2026.

RPRX past earnings growth

How has RPRX's earnings growth performed historically?

Company
-31.52%
Industry
58.15%
Market
54.79%
RPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

RPRX earnings history

Current Revenue
$2.3B
Current Earnings
$765.0M
Current Profit Margin
32.6%

RPRX Return on Equity

Current Company
7.8%
Current Industry
-21.3%
Current Market
35.2%
RPRX's Return on Equity (7.8%)... subscribe to Premium to read more.
High Return on Equity Performance

RPRX undefined

Current Company
4.2%
Current Industry
-8.8%
RPRX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RPRX announces earnings.

RPRX undefined

Current Company
5.55%
Current Industry
-3.4%
RPRX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RPRX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RPRX$1.04B$764.96M-2.40%$1.76
BNTX-$69.88M-$664.65MN/A-$2.76
UTHR$1.77B$1.27B+21.79%$28.48
GMAB$2.00B$1.47B+14.02%$2.34
INCY$1.68B$1.19B+25.56%$6.04
View Top Biotech Stocks

RPRX earnings dates

Next earnings date
Feb 10, 2026

Royalty Pharma Earnings Reports & History FAQ

What were Royalty Pharma's earnings last quarter?

On RPRX's earnings call on Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q3 2025 earnings per share (EPS) of $0.67, up 45.08% year over year. Total RPRX earnings for the quarter were $288.22 million. In the same quarter last year, Royalty Pharma's earnings per share (EPS) was $1.22.

If you're new to stock investing, here's how to buy Royalty Pharma stock.

When does Royalty Pharma report earnings?

The next RPRX earnings date is Invalid Date. Add RPRX to your watchlist to be reminded of Royalty Pharma's next earnings date.

Is Royalty Pharma profitable or losing money?

As of the last Royalty Pharma earnings report, Royalty Pharma is currently profitable. Royalty Pharma's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $764.96 million, a 33.2% decrease year over year.

What was RPRX's earnings growth in the past year?

As of Royalty Pharma's earnings date in Invalid Date, Royalty Pharma's earnings has grown -31.52% year over year. This is 89.67 percentage points lower than the US Biotechnology industry earnings growth rate of 58.15%. RPRX earnings in the past year totalled $764.96 million.

What are Royalty Pharma's earnings expectations?

The current EPS estimate for Royalty Pharma's earnings report in Invalid Date is $1.31.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.